Trade Ideas November 17, 2026 02:56 PM

Buy IDYA Ahead of Darovasertib NDA Momentum — Tactical Long with Clear Stops

Positive Phase 2/3 data, a sizeable cash cushion and oversold technicals make IDEAYA a tradable long into regulatory catalysts.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
IDYA

IDEAYA (IDYA) delivered convincing darovasertib combo data earlier this year and flagged an NDA submission for H2 2026. The stock is trading near $27.30 after a sharp pullback; balance-sheet strength, an attractive technical setup and a clear regulatory catalyst create a high-reward trade. This idea lays out entry, stop and target levels across horizons and the risks that could derail the thesis.

Buy IDYA Ahead of Darovasertib NDA Momentum — Tactical Long with Clear Stops
IDYA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Darovasertib + crizotinib showed materially better PFS (6.9 vs 3.1 months) and ORR (37.1% vs 5.8%), prompting an intended NDA submission in H2 2026.
  • IDYA trades at $27.30 with a market cap near $2.64B and cash of roughly $2.71B, giving it significant runway.
  • Technicals are oversold (RSI ~28.7) with notable short interest, creating both downside risk and squeeze potential.
  • Recommended long trade: entry $27.30, stop $24.50, target $40.00, long term (180 trading days).

Hook and thesis

IDEAYA Biosciences (IDYA) is a classic biotech setup where a single clinical program can re-rate the whole equity. The company reported compelling Phase 2/3 results for darovasertib combined with crizotinib in metastatic uveal melanoma - median progression-free survival of 6.9 months versus 3.1 months for standard therapy and an overall response rate of 37.1% versus 5.8% - and signaled plans to submit an FDA New Drug Application in the second half of 2026. With that catalyst in view, the market has swung from optimism to a pullback: IDYA opened the day at $30.42, traded intraday as high as $31.85 and is now at $27.30 after a volatile session.

My base case: stay bullish on IDYA into the darovasertib regulatory path, but trade it with strict risk controls. The company’s cash position and the clarity of clinical benefit justify a long trade with a disciplined stop. This is a binary-rich, high-volatility trade suited for risk-tolerant traders who can stomach biotech headline risk.

What IDEAYA does and why the market should care

IDEAYA is an oncology-focused precision medicine company developing targeted therapeutics for genetically defined cancers. Its leading program, darovasertib, targets the protein kinase C pathway and was tested in combination with crizotinib in metastatic uveal melanoma - a rare but aggressive cancer with few effective systemic options. The combination’s Phase 2/3 data materially improved PFS and response rate versus standard therapy; that is the fundamental driver behind the current price action and the company’s planned regulatory push.

Key financials and recent trends

Use of capital and balance-sheet strength are central to any biotech investment. Relevant datapoints:

  • Market capitalization: approximately $2.64 billion.
  • Cash on hand: roughly $2.71 billion, providing a meaningful runway and optionality for regulatory and commercial activities.
  • Enterprise value: approximately $2.67 billion, reflecting the market value plus liabilities.
  • Recent quarterly performance: Q3 reported a loss of $1.22 per share while producing $10.24 million in revenue, beating revenue consensus but down materially from $207.83 million in the year-ago quarter. The revenue collapse suggests last year included one-time partner or milestone receipts; current recurring revenue is limited.
  • Profitability metrics remain negative: trailing EPS is deep in the red at about -4.34 and return-on-assets and return-on-equity are negative, which is common for clinical-stage biotech names.

The takeaway: IDEAYA is a development-stage biotech with a strong cash base and a high-value catalyst in darovasertib. The company’s latest quarter beat revenue estimates but still shows the classic biotech profile of operating losses while advancing clinical programs.

Technical and market structure context

Price action has become stretched to the downside in the near term. Current price is $27.30, intraday low $26.68 and 52-week range $26.69 to $42.68. Momentum indicators are signaling oversold conditions - RSI is ~28.7 and the 10/20/50-day moving averages are above price (SMA50 around $35.05). Short interest is meaningful: recent settlement reports show between roughly 8.2 million and 10.1 million shares short with days-to-cover fluctuating in the single digits to mid-teens. Elevated short volume in recent sessions suggests the move lower has conviction but also the potential for squeeze dynamics if news turns positive.

Valuation framing

On headline multiples the stock looks expensive: price-to-sales and EV-to-sales ratios are very high (reflecting little near-term revenue), and EPS is deeply negative. Specifically, EV/sales sits above 70x, which is not unusual for a clinically dependent biotech where value is derived from potential future product sales and milestone license fees rather than current revenue. What matters here is pipeline potential relative to the market-capitalization and the regulatory path. With a market cap near $2.64 billion and cash roughly $2.71 billion, IDEAYA’s balance sheet is a relative strength; the cash cushion de-risks the equity to some extent by reducing near-term financing risk.

Catalysts to watch (2 to 5)

  • NDA submission and acceptance for darovasertib - timing and content of the filing will move the stock materially.
  • FDA feedback or meeting outcomes - an accepted NDA and a PDUFA target date or advisory committee scheduling would be major positives.
  • Additional clinical readouts or supportive safety data that expand the label opportunity beyond the initial indication.
  • Partnering, licensing or commercialization announcements that could accelerate revenue ramp or de-risk launch execution.

Trade plan

This is a directional long with a clearly defined stop. Trade specifics:

  • Trade direction: Long
  • Entry price: $27.30
  • Stop loss: $24.50
  • Target price (primary): $40.00
  • Time horizon: Long term (180 trading days) - allow time for regulatory review, potential NDA acceptance and early commercial planning signals.

Why these levels?

  • Entry at $27.30 captures the current pullback and exploits the oversold technical backdrop. Traders who missed the current print could set a limit near $27.00 to $27.50.
  • Stop at $24.50 sits below intraday lows and provides a buffer for headline-driven volatility while limiting downside. A break and close below $24.50 would indicate further deterioration in sentiment and raise questions about near-term buyer interest.
  • Target $40.00 is a disciplined, achievable level within the stock’s 52-week high of $42.68 if regulatory news is constructive and the broader biotech tape cooperates. Hitting $40 implies a re-rating alongside the transition from clinical readout to regulatory visibility and potential commercial optionality.

If you prefer shorter windows:

  • Short term (10 trading days): consider partial positions with the same stop and a nearer-term target of $31.50 to $33.00 to play a technical rebound.
  • Mid term (45 trading days): use the full stop described above and scale into the position if the stock stabilizes above $30.00 or on positive incremental news.

Risks and counterarguments

  • Regulatory risk: The FDA can delay, request new analyses or deny approval. Even with strong Phase 2/3 data, regulators can ask for additional safety or efficacy data that lengthen the timeline and compress the stock.
  • Binary headline risk: Biotech equities often move violently on single announcements. A negative safety signal or an unexpected comment from an FDA reviewer could push IDYA well below the stop level.
  • Commercial and market size uncertainty: Uveal melanoma is a small population; even with approval, how payers and clinicians adopt darovasertib will determine revenue scale. Past-quarter revenue collapse from $207.83 million to $10.24 million highlights how milestone-driven revenue can be lumpy.
  • Valuation sensitivity: EV/sales and P/S ratios are extremely high. If investors re-price the equity nearer-term on a multiple contraction, the stock could fall even on otherwise neutral news.
  • High short interest and volatile trading: while short interest can create squeeze dynamics, it also signals that a meaningful contingent of the market expects further downside. That can amplify selloffs in weak market environments.

Counterargument: One could reasonably avoid IDYA now because the company’s current revenue profile is low and last year’s revenue appears to have been driven by non-recurring events, making base valuation harder to justify absent a clear path to large, recurring sales. For investors who prioritize steady revenues and predictable cash flows, IDYA is not an appropriate holding.

Conclusion and what would change my mind

My stance: tactically bullish with a high-risk tolerance. The darovasertib data and the company’s stated intention to submit an NDA are powerful catalysts; combined with a substantial cash balance and oversold technicals, they justify a long trade with a clearly defined stop. This is not a buy-and-forget name; it is a catalyst-driven trade that must be monitored for regulatory updates and safety signals.

What would change my view: a formal FDA request for additional trials, a negative safety signal in the darovasertib program, or a meaningful miss on expected partnering/financial milestones would force reassessment and likely invalidate the trade. Conversely, an accepted NDA with a PDUFA date or a commercial partner announcement would prompt me to add to the position and raise target levels.

Quick reference table

Metric Value
Current Price $27.30
Market Cap $2.64B
Cash $2.71B
Recent Quarterly Rev $10.24M
Recent Quarterly EPS -$1.22
52-Week Range $26.69 - $42.68

Trade with position size that reflects the high binary risk of a regulatory biotech: keep the allocation small relative to total portfolio risk and use the $24.50 stop to protect capital. If you take the trade, set alerts for NDA acceptance, FDA communications and any partner/label news. Those events will determine whether the thesis plays out or needs to be cut short.

Risks

  • FDA could request additional data or delay/deny approval, severely compressing the stock.
  • Safety signals in ongoing studies or post-marketing could curtail uptake and value.
  • Revenue base is currently small and lumpy; milestone-driven revenue creates valuation uncertainty.
  • High short interest and volatile trading could amplify negative moves on any unfavorable news.

More from Trade Ideas

Buy the TPU-Led AI Inference Story: Alphabet as a Long-Term Trade Nov 17, 2026 AMD's AI Momentum: A Tactical Long While the AI Infrastructure Trade Rebalances Nov 17, 2026 Monte Rosa (GLUE): A High-Risk, High-Reward Contrarian Buy as the Market Sells Off Nov 17, 2026 Hershey Upgraded: Margin Recovery and Snack Growth Make $HSY a Buy Nov 17, 2026 Crocs After a Strong Print: Favor the Upside, But Trade for Stability Nov 17, 2026